Literature DB >> 7447951

Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.

R M Hagan, M J Raxworthy, P A Gulliver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7447951     DOI： 10.1016/0006-2952(80)90574-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  3 in total

1.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

2.  Central action of benserazide after COMT inhibition demonstrated in vivo by PET.

Authors:  J Tedroff; P Hartvig; P Bjurling; Y Andersson; G Antoni; B Långström
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.